A Phase I/II Study of Lapatinib Plus Myocet TM in Patients With HER2+ve Metastatic Breast Cancer Following Disease Progression During, or After, Treatment With Trastuzumab and Taxanes
Phase of Trial: Phase I/II
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Lapatinib (Primary) ; Doxorubicin liposomal
- Indications Breast cancer
- Focus Therapeutic Use
- 23 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 22 Jan 2014 Planned End Date changed from 1 Oct 2014 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
- 24 Dec 2011 New trial record